These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 34052798)

  • 1. [Hodgkin’s lymphoma-related vanishing bile duct syndrome].
    Boldizsár S; Rottek J; Schneider T; Varga F; Szaleczky E
    Orv Hetil; 2021 May; 162(22):884-888. PubMed ID: 34052798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vanishing bile duct syndrome as a presentation of Hodgkin's lymphoma.
    Fatima I; Mahadevia H; Madhusudhana S; Shrestha A
    BMJ Case Rep; 2024 May; 17(5):. PubMed ID: 38772873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [De novo inflammatory bowel disease in children after solid organ transplantation].
    Boros KK; Kelen K; Reusz G; Sallay P; Szabó A; Dezsőfi A
    Orv Hetil; 2021 May; 162(18):720-726. PubMed ID: 33934087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hodgkin's lymphoma-related vanishing bile duct syndrome: a case report and literature review.
    Wong KM; Chang CS; Wu CC; Yin HL
    Kaohsiung J Med Sci; 2013 Nov; 29(11):636-41. PubMed ID: 24183359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vanishing bile duct syndrome in Hodgkin's lymphoma: A case report and literature review.
    Bakhit M; McCarty TR; Park S; Njei B; Cho M; Karagozian R; Liapakis A
    World J Gastroenterol; 2017 Jan; 23(2):366-372. PubMed ID: 28127210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete remission of paraneoplastic vanishing bile duct syndrome after the successful treatment of Hodgkin's lymphoma: a case report and review of the literature.
    Rota Scalabrini D; Caravelli D; Carnevale Schianca F; D'Ambrosio L; Tolomeo F; Boccone P; Manca A; De Rosa G; Nuzzo A; Aglietta M; Grignani G
    BMC Res Notes; 2014 Aug; 7():529. PubMed ID: 25125318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.
    Behringer K; Goergen H; Hitz F; Zijlstra JM; Greil R; Markova J; Sasse S; Fuchs M; Topp MS; Soekler M; Mathas S; Meissner J; Wilhelm M; Koch P; Lindemann HW; Schalk E; Semrau R; Kriz J; Vieler T; Bentz M; Lange E; Mahlberg R; Hassler A; Vogelhuber M; Hahn D; Mezger J; Krause SW; Skoetz N; Böll B; von Tresckow B; Diehl V; Hallek M; Borchmann P; Stein H; Eich H; Engert A; ; ;
    Lancet; 2015 Apr; 385(9976):1418-27. PubMed ID: 25539730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.
    Duggan DB; Petroni GR; Johnson JL; Glick JH; Fisher RI; Connors JM; Canellos GP; Peterson BA
    J Clin Oncol; 2003 Feb; 21(4):607-14. PubMed ID: 12586796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vanishing bile duct syndrome related to DILI and Hodgkin lymphoma overlap: A rare and severe case.
    Greca RD; Cunha-Silva M; Costa LBE; Costa JGF; Mazo DFC; Sevá-Pereira T; Nascimento MMC; Pereira IE; Oliveira FC; Faria GAS; Neto FLP; Almeida JRS
    Ann Hepatol; 2020; 19(1):107-112. PubMed ID: 31537508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study.
    Agostinelli C; Gallamini A; Stracqualursi L; Agati P; Tripodo C; Fuligni F; Sista MT; Fanti S; Biggi A; Vitolo U; Rigacci L; Merli F; Patti C; Romano A; Levis A; Trentin L; Stelitano C; Borra A; Piccaluga PP; Hamilton-Dutoit S; Kamper P; Zaucha JM; Małkowski B; Kulikowski W; Tajer J; Subocz E; Rybka J; Steidl C; Broccoli A; Argnani L; Gascoyne RD; d'Amore F; Zinzani PL; Pileri SA
    Lancet Haematol; 2016 Oct; 3(10):e467-e479. PubMed ID: 27692305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vanishing Bile Duct Syndrome in the Presence of Hodgkin Lymphoma.
    Gaudel P; Brown P; Byrd K
    Cureus; 2022 Jul; 14(7):e26842. PubMed ID: 35974868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vanishing bile duct syndrome: a rare cause of jaundice in Hodgkin's lymphoma.
    Amer S; Muqeetadnan M; Rahman A; Nusrat S; Hassan S
    Turk J Gastroenterol; 2013; 24(5):444-6. PubMed ID: 24557970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A rare presentation of vanishing bile duct syndrome in Hodgkin lymphoma: Case report.
    Patodiya B; Ramani VK; Rao PN; Sharma M; Patodiya S; Reddy DN
    SAGE Open Med Case Rep; 2023; 11():2050313X231208968. PubMed ID: 37954540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group.
    Meyer RM; Gospodarowicz MK; Connors JM; Pearcey RG; Bezjak A; Wells WA; Burns BF; Winter JN; Horning SJ; Dar AR; Djurfeldt MS; Ding K; Shepherd LE; ;
    J Clin Oncol; 2005 Jul; 23(21):4634-42. PubMed ID: 15837968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.
    Younes A; Connors JM; Park SI; Fanale M; O'Meara MM; Hunder NN; Huebner D; Ansell SM
    Lancet Oncol; 2013 Dec; 14(13):1348-56. PubMed ID: 24239220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pulmonary necrotizing sarcoid granulomatosis].
    Zombori-Tóth N; Ugocsai K; Vincze Á; Furák J; Tiszlavicz L; Iványi B; Zombori T
    Orv Hetil; 2021 Sep; 162(38):1541-1547. PubMed ID: 34537719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutropenia and febrile neutropenia in patients with Hodgkin's lymphoma treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy.
    Chand VK; Link BK; Ritchie JM; Shannon M; Wooldridge JE
    Leuk Lymphoma; 2006 Apr; 47(4):657-63. PubMed ID: 16690524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma.
    Avigdor A; Bulvik S; Levi I; Dann EJ; Shemtov N; Perez-Avraham G; Shimoni A; Nagler A; Ben-Bassat I; Polliack A
    Ann Oncol; 2010 Jan; 21(1):126-32. PubMed ID: 19608615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vanishing bile duct syndrome: a possible mechanism for intrahepatic cholestasis in Hodgkin's lymphoma.
    Hubscher SG; Lumley MA; Elias E
    Hepatology; 1993 Jan; 17(1):70-7. PubMed ID: 7678577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
    Sieber M; Tesch H; Pfistner B; Rueffer U; Lathan B; Brosteanu O; Paulus U; Koch T; Pfreundschuh M; Loeffler M; Engert A; Josting A; Wolf J; Hasenclever D; Franklin J; Duehmke E; Georgii A; Schalk KP; Kirchner H; Doelken G; Munker R; Koch P; Herrmann R; Greil R; Anselmo AP; Diehl V
    J Clin Oncol; 2002 Jan; 20(2):476-84. PubMed ID: 11786577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.